Oppenheimer analyst Jay Olson lowered the firm’s price target on Crispr Therapeutics to $95 from $102 and keeps an Outperform rating on the shares. Crispr reported Q1 results and the firm was “delighted” to see the progress of the internal progress especially on the emerging in vivo franchise with additional preclinical data shared at ASGCT, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
- Crispr Therapeutics price target lowered to $65 from $70 at Wells Fargo
- Crispr Therapeutics price target raised to $52 from $46 at Baird
- Crispr Therapeutics price target lowered to $67 from $80 at Barclays
- CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results